← Back to Search

Virus Therapy

PUUV DNA Vaccine for Hemorrhagic Fever with Renal Syndrome (HTNV/PUUV Trial)

Phase 1
Waitlist Available
Led By James E Moon, MD
Research Sponsored by U.S. Army Medical Research and Development Command
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Awards & highlights
No Placebo-Only Group

Summary

The purpose of this study is: • To assess safety and tolerability of the HTNV and PUUV DNA vaccines, pWRG/HTN-M(x) and pWRG/PUUV-M(s2), administered intramuscularly using a TDS-IM electroporation device Secondary: • To evaluate clinical immunogenicity of the HTNV and PUUV DNA vaccines, pWRG/HTN-M(x) and pWRG/PUUV-M(s2), including an assessment of the acute procedure tolerability when administered with the TDS-IM electroporation.

Eligible Conditions
  • Hemorrhagic Fever with Renal Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from baseline for Unsolicited adverse events after each vaccination
Change from baseline for solicited adverse events after each vaccination
Secondary study objectives
Change in neutralizing antibody levels from baseline to post vaccination

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: PUUV DNA VaccineExperimental Treatment1 Intervention
This group will receive Puumala Virus DNA Vaccine only
Group II: HTNV DNA VaccineExperimental Treatment1 Intervention
This group will receive Hantaan Virus DNA Vaccine only
Group III: HTNV + PUUVExperimental Treatment1 Intervention
This group will receive a 1:1 mixture of HTNV and PUUV DNA Vaccines
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vaccine/device combination for prevention of HFRS
2012
Completed Phase 1
~40

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

U.S. Army Medical Research and Development CommandLead Sponsor
290 Previous Clinical Trials
246,140 Total Patients Enrolled
4 Trials studying Hemorrhagic Fever with Renal Syndrome
312 Patients Enrolled for Hemorrhagic Fever with Renal Syndrome
US Army Medical Research Institute of Infectious DiseasesFED
13 Previous Clinical Trials
1,357 Total Patients Enrolled
1 Trials studying Hemorrhagic Fever with Renal Syndrome
130 Patients Enrolled for Hemorrhagic Fever with Renal Syndrome
United States Army Medical Materiel Development ActivityFED
10 Previous Clinical Trials
19,401 Total Patients Enrolled
1 Trials studying Hemorrhagic Fever with Renal Syndrome
130 Patients Enrolled for Hemorrhagic Fever with Renal Syndrome
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top